Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the company's growth and performance during the specified Class Period [1][4]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company specializing in cataract treatment, with its main product being the RxSight Light Adjustable Lens system, which includes an intraocular light adjustable lens and a light delivery device [3]. Allegations of the Lawsuit - The lawsuit claims that RxSight and its executives misrepresented the company's growth, stating that utilization was rising and that newer customer cohorts were adopting the technology at a comparable or faster rate than previous cohorts. In reality, the company faced challenges with its field organization, leading to slower adoption and declining utilization [4]. - The lawsuit highlights that incremental placements of light delivery devices did not result in the expected volume of lens procedures, undermining the company's growth model [4]. Impact of Disclosures - On April 2, 2025, RxSight reported a sequential decline in quarterly lens sales and reduced its full-year revenue guidance by approximately $24 million, resulting in a 38% drop in the stock price [5]. - Further disclosures on July 8, 2025, revealed a 45% sequential decline in light delivery device sales and a second consecutive quarter of declining lens sales, leading to another 38% decrease in stock price [6]. Legal Representation - The plaintiffs in the lawsuit are represented by Robbins Geller Rudman & Dowd LLP, a law firm with significant experience in prosecuting investor class actions related to financial fraud [7].

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between May 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”, of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO D ...